Aikido Pharma Inc (NASDAQ: AIKI) Files Patent Submission for the Use of Ketamine to Treat Alzheimer’s Disease

Aikido Pharma Inc (NASDAQ: AIKI) announced that the company had filed a provisional patent application to use ketamine and peptides to handle Alzheimer’s disease. The company beforehand protected and announced patent rights for the use of peptides as a drug distribution scheme. This patent request seeks patent defense for the usage of ketamine and these peptides to treat Alzheimer’s illness.

Disease hints at shortfalls in cognitive purpose

Alzheimer’s disease is an advanced neurodegenerative complaint associated with the obliteration of higher brain constructions. 

The disease leads to shortfalls in reasoning purpose and failures in reminiscence, knowledge, verbal, and aptitude to perform deliberate and focused actions. Alzheimer’s disease is also supplemented by attendant social, expressive, relational, and social worsening. 

Directed delivery of a drug, prodrug, or healing agent to booths that cause an illness or are affected by sickness can advance the treatment of the illness. There is a necessity for the directed distribution of drugs, prodrugs, or other healing agents to treat Alzheimer’s. 

In other news, the company has announced that encouraging Phase 1 challenging data was offered at the 2021 ASCO Annual Meeting on June 4, 2021. The placard exhibition of the data was by Dr. Scott Tagawa, a Professor of Medicine & Urology at Weill Cornell Medicine and an AIkido Pharma Scientific Advisory Board member. 

Climaxes from the arrangement comprising:

Deteriorating PSA heights in treated patients

Deteriorating mingling tumor cell total in treated patients

Actinium-225 radiolabeled J591 well-tolerated with an initial indication of effectiveness in a deeply pre-treated patient populace

Actinium-225 radiolabeled J591 benign at the verified amount

Phase 2 pilot ongoing

Neal Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, specified, “The Phase I trial consequences of the 225Ac-J591 antibody for patients with widespread tumor load are imposing, PSA failures and CTC replies were obvious.”

Leave a Comment

Your email address will not be published.